Clinical trials: Evaluation of QTc Interval
Healthy Volunteers
The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects
This study has been designed to investigate the effect of lersivirine on the QT/QTc interval in order to help establish the safety profile of lersivirine.
- Trial name
- NCT00936871
- Testing
- Lersivirine, Lersivirine (if necessary), Moxifloxacin
- Where
- Belgium
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval
This is a 2 part study to evaluate the safety and tolerability of supra-therapeutic doses of RO4602522 (Part A); and to investigate the effect of RO4602522 on the QTcF interval in healthy volunteers (Part B).
- Trial name
- NCT02104648
- Testing
- RO4602522, moxifloxacin
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prolonged QTc Interval, Pharmacokinetic
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects
The objective of this study was to evaluate the effects of cebranopadol (GRT6005) on the electrical activity of the heart in healthy participants.
- Trial name
- NCT03958123
- Testing
- 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol
- Where
- United States
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Healthy Subjects
A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
This thorough QT (TQT) study will take place in healthy subjects administered single doses of study drug. It will be a randomized, double-blind, placebo and active-controlled, 4-treatment crossover study.
- Trial name
- NCT02222324
- Testing
- E2609, Moxifloxacin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Carcinoma
A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be…
- Trial name
- NCT00477425
- Sponsor
- Genentech, Inc.
Healthy
Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects
The purpose of this study is to assess the affect that PF-00232798 has on QT interval. A prolonged QT interval is a risk factor for arrhythmias.
- Trial name
- NCT01140425
- Testing
- PF-00232798, Moxifloxacin
- Where
- Singapore
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.
- Trial name
- NCT07422298
- Testing
- BMS-986278, Moxifloxacin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Prolonged QTc Interval
Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Randomized, single-dose, double-blind, placebo and active controlled, four-period crossover study to evaluate the effect of deferiprone on QTc prolongation after administration of a single therapeutic (33 mg/kg) and…
- Trial name
- NCT01860703
- Testing
- Deferiprone, moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ApoPharma
Healthy
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
The main purpose of this study is to assess the effect of Selpercatinib (LY3527723) on the heart rate-corrected QT (QTc) interval. The study will last up to 41 days.
- Trial name
- NCT05630274
- Testing
- Selpercatinib, Moxifloxacin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat
The primary objective of this study was to investigate whether there is a clinically meaningful effect on QTc change from baseline relative to placebo after administration of 10 mg at steady state in patients with stable CAD…
- Trial name
- NCT03504982
- Testing
- Vericiguat (BAY1021189), Moxifloxacin
- Where
- 8 sites in Germany, Moldova and 1 more
- Volunteers
- 74 people
- Sponsor
- Bayer
Advanced Solid Tumors
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
The purpose of this study is to obtain QTc data, to assess the effects of tivozanib on ECG morphology, and to determine the pharmacokinetic pharmacodynamic (PK-PD) relationship between any observed changes in cardiac…
- Trial name
- NCT01210846
- Testing
- tivozanib
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Healthy
A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)
Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often.
- Trial name
- NCT07305831
- Testing
- Ulonivirine, Moxifloxacin
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infection, Human Immunodeficiency Virus
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
This study is being conducted to comply with the Food and Drug Administration (FDA) recommendation that all new non anti-arrhythmic drugs be assessed for cardiac repolarization effects through electrocardiographic evaluation.
- Trial name
- NCT02027454
- Testing
- GSK1265744, Moxifloxacin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cancer, Solid Tumor
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.
- Trial name
- NCT01017731
- Testing
- IMC-1121B, Moxifloxacin, Diphenhydramine
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Diabetes
Effect of Glucose on QTc Interval in Type 1 Diabetes
High blood glucose levels (hyperglycaemia) and Moxifloxacin (a commonly used antibiotic) have both been shown independently to affect heart activity in healthy volunteers as recorded by ECG. i.e.
- Trial name
- NCT01984827
- Testing
- Moxifloxacin, hyper-glycaemic clamp
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richmond Research Institute
Human Experimentation (Human Volunteers)
Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers
This phase I trial will evaluate the effects of rupatadine, at a dose of 10 mg OD (authorised and marketed dose) and the 100mg/day (supratherapeutic dose) on the ECG parameters with a special focus on its effect on cardiac…
- Trial name
- NCT00199225
- Testing
- Rupatadine, moxifloxacin, Continous electrocardiographic register
- Where
- Spain
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company
Healthy Volunteers, Healthy
A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
This is a partially double-blind study in healthy adult subjects, which will be conducted as a placebo- and active-controlled, single-dose, crossover study.
- Trial name
- NCT03164109
- Testing
- GC4419 IV, Oral moxifloxacin
- Where
- Australia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Cancer
A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters…
- Trial name
- QUTIE (NCT00876044)
- Testing
- aflibercept (AVE0005)
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 88 people
- Sponsor
- Sanofi
Healthy
A Study of LY3039478 in Healthy Participants
The main purpose of this study is to investigate the safety of the study drug known as LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part A has three periods.
- Trial name
- NCT02659865
- Testing
- LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1), LY3039478 Formulated Capsule (Test, Formulation 3)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company